Samsamshariat Shiva, Sharifi-Sade Mehdi, Zoofaghari Shafeajafar, Mehr Asieh Maghami, Sabzghabaee Ali Mohammad
Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of General Medicine, Islamic Azad University Najafabad Branch, Isfahan, Iran.
J Res Pharm Pract. 2021 Aug 3;10(2):96-101. doi: 10.4103/jrpp.JRPP_21_31. eCollection 2021 Apr-Jun.
Acute low back pain is a common ailment and causes pain and disability. Physicians often prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) to treat acute low back pain; however, due attention has recently been drawn to muscle relaxants to reduce the severity of patients' daily physical dysfunction. Therefore, this study aimed to evaluate the therapeutic effect of the administration of indomethacin alone compared with methocarbamolas a muscle relaxant and indomethacin as an NSAID on the treatment of acute low back pain.
The present double-blind clinical trial was performed on 64 patients with acute low back pain. The patients were categorized into two groups and received the treatments as follows. Indomethacin capsules of 25 mg every 8 h and placebo tablets every 8 h were administered in the first group (Group I). Indomethacin capsules of 25 mg every 8 h and methocarbamol tablets of 500 mg every 8 h were administered in the second group (Group I + M). Patient pain intensity and physical function based on Back Pain Function Scale (BPFS) were recorded before and 1 week after the intervention.
The present study results revealed that the mean pain reduction of patients in Group I + M was significantly higher than that of Group I (3.66 ± 3.17 vs. 1.84 ± 1.53; < 0.001). Moreover, the mean BPFS increase in Group I + M was significantly higher than that of Group I (19.44 ± 8.66 vs. 4.75 ± 4.35; < 0.001).
According to the results of the present study, concomitant administration of indomethacin and methocarbamol can be more effective in reducing pain intensity and improving the patient's physical function (or performance).
急性下腰痛是一种常见疾病,会导致疼痛和功能障碍。医生常开具非甾体抗炎药(NSAIDs)来治疗急性下腰痛;然而,近来肌肉松弛剂在减轻患者日常身体功能障碍的严重程度方面受到了更多关注。因此,本研究旨在评估单独使用吲哚美辛与作为肌肉松弛剂的美索巴莫及作为NSAIDs的吲哚美辛联合使用对急性下腰痛的治疗效果。
本双盲临床试验对64例急性下腰痛患者进行。患者被分为两组并接受如下治疗。第一组(I组)每8小时服用25毫克吲哚美辛胶囊及每8小时服用安慰剂片。第二组(I + M组)每8小时服用25毫克吲哚美辛胶囊及每8小时服用500毫克美索巴莫片。在干预前及干预1周后,根据背痛功能量表(BPFS)记录患者的疼痛强度和身体功能。
本研究结果显示,I + M组患者的平均疼痛减轻程度显著高于I组(3.66±3.17对1.84±1.53;<0.001)。此外,I + M组的平均BPFS增加幅度显著高于I组(19.44±8.66对4.75±4.35;<0.001)。
根据本研究结果,吲哚美辛与美索巴莫联合使用在减轻疼痛强度和改善患者身体功能(或表现)方面可能更有效。